10-41 wrote - "Something doesn't add up here!"
That is for sure.
- Strange financings required for a drug with break through designation and excellent independent scientific papers, but not unusual financings for RVX.
- Financings which completely undervalue the assets like an 8 year lead in CVD epigenetics.
- A couple of months have past since the original announced start of the Covid trial.
- The usual lack of communication.
I'd like to believe that great things are happening behind the scenes but look at the track record.
On a separte thought the other thing that struck me in the Globe article is Moderna's approach to drug development through technology on computers, not in the lab. It's similar in concept to Repare Therapeutics SNIPRx developed from CRISPR to develop targetted cancer drugs. All I know about RVX and Zenith is that they have about 4000 compounds or molecules. I'm not a scientist but RVX seems dated to me.
Perhaps there is a breakthrough deal in the works. :)
GLTA
Toinv
